Skip to main content

Table1 Characteristics of 357 Delta variant–infected patients with different vaccination statuses

From: Impact of inactivated COVID-19 vaccines on lung injury in B.1.617.2 (Delta) variant-infected patients

 

Unvaccinated (n = 105)

Partially Vaccinated (n = 72)

Fully Vaccinated (n = 180)

P-value

Demographics and clinical characteristics

Sex

 Male

40 (38.1)

35 (48.6)

67 (37.2)

0.233

 Female

65 (61.9)

37 (51.4)

113 (62.8)

 

Age, years

67.00 [52.00, 74.00]

51.00 [39.75, 67.25]

44.00 [37.00, 52.00]

 < 0.001

 18–59

36 (34.3)

46 (63.9)

167 (92.8)

 < 0.001

  ≥ 60

69 (65.7)

26 (36.1)

13 (7.2)

 

 With any comorbidity

45 (42.9)

23 (31.9)

33 (18.3)

 < 0.001

 Hypertension

34 (32.4)

18 (25.0)

23 (12.8)

 < 0.001

 Diabetes

13 (12.4)

7 (9.7)

9 (5.0)

0.069

 Heart disease

7 (6.7)

2 (2.8)

2 (1.1)

0.029

 Tumor

6 (5.7)

1 (1.4)

1 (0.6)

0.013

 Asthma

4 (3.8)

0 (0.0)

2 (1.1)

0.143

 Autoimmune diseases

1 (1.0)

1 (1.4)

2 (1.1)

1.000

 Time from illness onset to hospitalization

3.00 [2.00, 5.00]

3.00 [1.00, 4.00]

2.00 [1.00, 4.00]

0.004

Symptoms

 Fever

38 (36.2)

26 (36.1)

48 (26.7)

0.148

 Cough

50 (47.6)

35 (48.6)

94 (52.2)

0.743

 Shortness of breath

7 (6.7)

3 (4.2)

2 (1.1)

0.029

 Loss of smell or taste

2 (1.9)

2 (2.8)

11 (6.1)

0.212

 Stuffy nose or runny nose

9 (8.6)

9 (12.5)

32 (17.8)

0.088

 Pharyngeal discomfort

21 (20.0)

20 (27.8)

41 (22.8)

0.464

Blood laboratory findings

 C-reactive protein-mg/L

4.89 [0.50, 12.01]

6.77 [2.46, 20.12]

5.72 [2.20, 14.24]

0.177

  > 10

31 (29.5)

32 (44.4)

63 (35.0)

0.126

 Interleukin-6, pg/mL

16.93 [8.73, 28.58]

15.97 [4.77, 25.06]

5.92 [1.50, 13.57]

 < 0.001

  > 7

84 (80.8)

51 (71.8)

77 (43.0)

 < 0.001

 Lymphocyte count, × 109/L

1.07 [0.90, 1.44]

1.29 [0.90, 1.69]

1.17 [0.88, 1.56]

0.210

  < 0.8

21 (20.0)

14 (19.4)

28 (15.6)

0.560

 LDH, IU/L

245.00 [214.00, 292.00]

244.50 [203.50, 282.75]

230.5 [197.75, 269.25]

0.068

  > 245

52 (49.5)

36 (50.0)

72 (40.0)

0.186

 D-dimer, mg/L

0.40 [0.27, 0.64]

0.41 [0.28, 0.62]

0.35 [0.21, 0.58]

0.083

  > 0.55

35 (33.3)

21 (29.2)

48 (26.7)

0.481

Microbiological and serological data

 SARS-COV-2 IgM, S/CO

0.06 [0.03, 0.31]

0.37 [0.08, 1.26]

0.34 [0.11, 1.24]

 < 0.001

 IgM positive

16 (15.2)

20 (27.8)

55 (30.6)

0.012

 SARS-COV-2 IgG (S/CO)

0.10 [0.05, 0.26]

0.52 [0.15, 2.24]

5.56 [2.35, 34.87]

 < 0.001

 IgG Positive

14 (13.3)

28 (38.9)

152 (84.4)

 < 0.001

 Viral load (Ct value)

 ORF1ab gene

23.00 [20.00, 27.00]

24.50 [20.00, 29.00]

22.00 [19.00, 27.00]

0.179

 N gene

20.00 [17.00, 24.00]

20.50 [16.75, 26.00]

19.50 [15.00, 24.00]

0.166

  1. Data were expressed as median (interquartile range, IQR) or n (%). As appropriate, a comparison between groups was made using Mann–Whitney U-test, Chi-Square test, or Fisher’s exact test. Ct, cycle threshold; SARS-COV-2, severe acute respiratory syndrome coronavirus 2. The Ct value was used to represent the viral load of SARS-COV-2 in the upper respiratory tract